Matinas BioPharma
MTNB
28 hedge funds and large institutions have $177K invested in Matinas BioPharma in 2026 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 7 reducing their positions, and 5 closing their positions.
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
1.38% less ownership
Funds ownership: 6.91% → 5.53% (-1.4%)
7% less funds holding
Funds holding: 30 → 28 (-2)
32% less capital invested
Capital invested by funds: $260K → $177K (-$83K)
71% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$5.76K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$2.38K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$4 |
| 4 |
BWL
Bogart Wealth LLC
Mclean,
Virginia
|
+$1 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
-$27.2K |
| 2 |
Jane Street
New York
|
-$9.32K |
| 3 |
VF
Virtu Financial
New York
|
-$9K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$8.79K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$4.25K |
MTNB Hedge Fund Activity: Q1 2026 in Review
28 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q1 2026, worth a combined $177K — down 32% from $260K a quarter earlier.
Fund positioning in MTNB was balanced in Q1 2026: 5 funds opened new positions, 5 closed out, 2 added to existing stakes and 7 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $5.76K. The largest seller was DRW Securities, exiting entirely with an estimated $27.2K sold.
- 28 institutional investors held Matinas BioPharma (MTNB) as of Q1 2026, down from 30 in Q4 2025.
- Funds reported $177K of Matinas BioPharma stock for Q1 2026, down 32% quarter-over-quarter.
- 5 funds opened new Matinas BioPharma positions in Q1 2026 and 5 closed out, a net change of 0 holders.
- The largest Matinas BioPharma buyer in Q1 2026 was Geode Capital Management, an estimated $5.76K added.
- The largest Matinas BioPharma seller in Q1 2026 was DRW Securities, an estimated $27.2K sold.
Based on aggregated 13F filings for Q1 2026.